Cutaneous Malignant Melanoma is a form of cancer of the skin arising from melanocytes on the external surface of the skin. It can occur anywhere on the body and is more aggressive than the other two forms of skin cancer (basal cell and squamous cell non-melanoma cell skin cancer). Melanoma is the result of a combination of genetic / phenotypic predisposition and environmental catalysts.
This report provides the current incident population for Malignant Melanoma across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Sweden, Norway, Japan, China, Russia, Australia, Canada, Turkey, South Africa, Saudi Arabia, South Korea, Argentina, Brazil and Mexico) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Malignant Melanoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Malignant Melanoma include:
• Family history of Malignant Melanoma
• Atypical nevus syndrome
• Exposure to UV light
• Skin colour
• History of Sun burn
• Cutaneous reaction to sun exposure (freckling, inability to tan, sunburn tendency)
• > 50 common moles
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Malignant Melanoma’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Malignant Melanoma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Malignant Melanoma’s incident population.
• Identify sub-populations within Malignant Melanoma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Malignant Melanoma patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Malignant Melanoma Incidence
• Stages and Subtype of Malignant Melanoma
o Staging of Malignant Melanoma
o Location of Malignant Melanoma
o Clark’s Subtype of Malignant Melanoma
• Biomarkers and Mutations in Malignant Melanoma
o LDH Status in Stage III Malignant Melanoma
o BRAF Mutations in Malignant Melanoma
o NRAS Mutations in Malignant Melanoma
• Estimates of Treatment Eligible Malignant Melanoma Patients
o Treated patients with BRAF+ Cutaneous Malignant Melanoma
o Treated patients with BRAF wild-type Cutaneous Malignant Melanoma
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• Increase in cutaneous melanoma incidence by gender in the UK
List of Tables
• UICC / AJCC Staging for Melanoma
• Clark’s Classification of Melanoma
• Clark’s Subtype of Melanoma
• Average survival rates for Melanoma by Breslow’s thickness
• Incidence of Malignant Melanoma, total (000s)
• Incidence of Malignant Melanoma, males (000s)
• Incidence of Malignant Melanoma, females (000s)
• AJCC staging in Malignant Melanoma patients, total (000s)
• AJCC Stage III breakdown for Malignant Melanoma patients, total (000s)
• Location of Malignant Melanoma, total (000s)
• Clark’s Subtype of Malignant Melanoma, total (000s)
• LDH Status in Stage III Malignant Melanoma, total (000s)
• Malignant Melanoma with BRAF mutation, total (000s)
• BRAF mutation types in Malignant Melanoma patients, total (000s)
• Acral-Lentiginous Malignant Melanoma with BRAF mutation, total (000s)
• Malignant Melanoma with NRAS mutation, total (000s)
• NRAS mutation types in Malignant Melanoma patients, total (000s)
• Treated Patients by line for Malignant Melanoma, BRAF mutation positive (000s)
• Treated Patients by line for Malignant Melanoma, BRAF wild-type (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• USA Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• France Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• France Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Germany Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Germany Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Italy Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Italy Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Spain Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Spain Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• United Kingdom Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• United Kingdom Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Turkey Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Turkey Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Russia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Russia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Japan Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Japan Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• China Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• China Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• South Korea Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• South Korea Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Sweden Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Sweden Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Norway Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Norway Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Australia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Australia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Canada Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Canada Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Argentina Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Argentina Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Brazil Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Brazil Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Mexico Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Mexico Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• South Africa Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• South Africa Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
